Latanoprost/Timolol Stada

Latanoprost and Timolol, the active ingredients in Latanoprost/Timolol Stada, are a prostaglandin analog and a non‑selective beta‑blocker presented as an ophthalmic solution for ocular (topical) use. The combination is indicated for lowering intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension. GNH USA supplies Latanoprost/Timolol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost/Timolol is used in the management of glaucoma‑related conditions to reduce intra‑ocular pressure.

Open‑angle glaucoma: lowers intra‑ocular pressure to prevent optic nerve damage. Ocular hypertension: reduces pressure to lower the risk of progression to glaucoma. Combination therapy for ocular hypertension: provides additive pressure reduction when monotherapy is insufficient.

Latanoprost/Timolol may cause ocular and systemic adverse reactions.

Common Side Effects: - Eye irritation or burning sensation - Blurred vision shortly after instillation - Conjunctival hyperemia (redness) - Increased eyelash growth - Darkening of the iris color - Foreign body sensation in the eye

Serious or Rare Side Effects: - Allergic eye reaction (e.g., swelling, rash) - Severe eye pain or corneal ulceration - Marked bradycardia or heart block - Bronchospasm or worsening asthma - Systemic beta‑blocker effects (e.g., hypotension) - Acute angle‑closure glaucoma (rare).

Before prescribing Latanoprost/Timolol, clinicians should consider several safety aspects.

Assess baseline intra‑ocular pressure: ensure appropriate measurement before initiation. Screen for beta‑blocker contraindications: avoid in patients with severe asthma, COPD, or bradycardia. Monitor for ocular irritation: advise patients to report persistent redness or pain. Avoid use in patients with known hypersensitivity to prostaglandins or beta‑blockers. Store at room temperature: keep bottle tightly closed, protect from light and freezing.

Latanoprost/Timolol can interact with other systemic or ocular agents.

Major Interactions (Avoid): - Non‑selective beta‑blockers (e.g., propranolol) – risk of additive bradycardia. - Asthma or severe COPD medications – may exacerbate bronchospasm. - Cardiac conduction drugs (e.g., digoxin) – increased risk of heart block. - Other ocular beta‑blocker drops – excessive IOP lowering. - Systemic antihypertensives – may potentiate hypotension.

Moderate Interactions (Monitor Closely): - Carbonic anhydrase inhibitor eye drops – additive IOP reduction. - Other prostaglandin analogs – risk of ocular hyperemia. - Anticholinergic eye drops – possible reduced efficacy. - Systemic MAO inhibitors – monitor for cardiovascular effects. - Herbal supplements affecting blood pressure – observe for changes in IOP control.